For years, the GLS Capital team has been a united front in designing litigation finance solutions for businesses and law firms.
Our principals rely on years of experience as underwriters at the world’s largest litigation finance providers and as litigators at elite law firms.
MANAGEMENT BACKGROUND & EXPERIENCE
Adam Gill is a founder and Managing Director at GLS Capital and leads patent-related investments. Adam has evaluated hundreds of patent opportunities and has underwritten and managed hundreds of millions of dollars of litigation finance investments. He has led cases and investments in which his clients and counterparties have obtained more than $700 million in settlements and verdicts.
Adam’s experience in litigation finance began in 2013 when he joined Gerchen Keller Capital, LLC (“GKC”) as its first employee and led its patent investment team as the firm grew from $100 million AUM into the world’s largest private fund focused on legal and regulatory risk in 2016, with $1.4 billion AUM. After GKC was acquired by Burford in December 2016, Adam served as a Principal at Burford.
Prior to joining GKC, Adam was a partner in the patent litigation group of Kirkland & Ellis LLP in Chicago. Before joining K&E in 2004, Adam was a litigator in the Silicon Valley office of Dechert LLP, where he practiced patent, trade secret, securities and antitrust litigation. Adam holds a J.D. from the University of California-Hastings College of the Law and a B.A. from the University of South Carolina.
Jamison “Jamie” Lynch is a founder and Managing Director at GLS. Jamie leads GLS investments in life sciences and special situations.
Jamie is a former Principal at GKC where he led the firm’s life sciences investments, including those involving patent litigation. Jamie joined GKC in 2016 and assumed management of the firm’s investments and underwriting for matters involving product development, regulatory approval, and litigation regarding medical devices, pharmaceutical products, health care and other life sciences matters. After GKC was acquired by Burford in December 2016, Jamie served as a Principal at Burford.
Prior to joining GKC, Jamie co-led the global patent litigation team at Gilead Sciences, Inc. (“Gilead”). At Gilead, Jamie led global litigation strategy and execution, including Hatch-Waxman litigation, for products representing $19 billion in annual revenue.
Prior to joining Gilead, Jamie was a partner at Mayer Brown, where he actively involved in pharmaceutical patent litigation, patent prosecution and due diligence in the firm’s Chicago and Frankfurt offices. Before Mayer Brown, Jamie represented generic companies in Hatch-Waxman disputes at Schiff Hardin and Leydig, Voit & Mayer. Jamie holds a J.D. and B.S. (mechanical engineering, with additional significant coursework in chemistry) from the University of Wisconsin.
David Spiegel is a founder and Managing Director of GLS. David leads commercial litigation and arbitration-related investing at GLS, having previously led investment teams at the world’s two largest litigation finance firms.
David has deep experience originating, underwriting, and managing litigation finance investments related to claims of breach of contract, fraudulent conveyance, antitrust, judgment enforcement, and investor-state arbitration, among others. David also has consulted and testified as an expert in high-profile disputes regarding the valuation of litigation assets.
Prior to entering litigation finance, David was a litigator in the Chicago office of Kirkland & Ellis LLP, where he represented clients in a wide array of industries. He holds a J.D. from the University of Pennsylvania Law School, an MSc from the London School of Economics, and a B.A. from Northwestern University.
Colleen Arciniegas, CPA
Chief Financial Officer
Colleen Arciniegas serves as the Chief Financial Officer at GLS. She is also a member of the GLS portfolio and valuation committees.
Colleen joins GLS from Gladius Capital Management LP, a large investment adviser firm focused on derivatives and volatility, where she served as the Chief Financial Officer since 2012. At Gladius, Colleen was responsible for the firm’s financial planning and reporting, investor reporting and all financial and accounting regulatory requirements. Colleen also built and led Gladius’ fund accounting team and oversaw all aspects of the accounting for the firm’s funds and separately managed accounts, as well as the management company, including all valuation, audit and tax work.
Prior to joining Gladius, Colleen was a Director of UBS O’Connor LLC, a division of UBS Asset Management. Colleen served as the group leader of the product control team at O’Connor, a large single and multi-manager hedge fund platform. Before joining O’Connor in 2004, Colleen was an audit professional within the Investment Management Group of Deloitte.
Colleen holds a B.S. in Accountancy from the University of Illinois at Urbana-Champaign. She is also a Certified Public Accountant.
Jeffery Lula serves as a Principal at GLS and is responsible for due diligence and monitoring of commercial litigation and arbitration-related investments.
Prior to joining GLS, Jeff was a litigation partner at Kirkland & Ellis LLP in Chicago. During his nine years at Kirkland, Jeff’s practice focused on a wide variety of complex commercial litigation, including contract disputes, bankruptcy litigation, corporate mismanagement, fraudulent transfer litigation, and insurance litigation. His experience extends to all stages of litigation and appeal, and he also counseled clients during internal investigations prior to litigation or arbitration. He has represented clients in a variety of fields, including private equity firms, insurance carriers, and large Chapter 11 debtors.
Jeff holds a J.D. from the University of Chicago Law School, where he served as an Articles’ Editor of the University of Chicago Law Review, and a B.S. from University of Illinois.
Joel Merkin serves as a Principal at GLS and is responsible for due diligence and monitoring of patent investments.
Prior to joining GLS, Joel was a partner in the intellectual property litigation group at Kirkland & Ellis LLP in Chicago, where he practiced for over a decade. At Kirkland, Joel’s practice focused on complex patent litigation before federal district courts, the Patent Trial and Appeal Board (PTAB), the International Trade Commission (ITC), and the Federal Circuit.
Joel is a registered patent attorney and uses his patent litigation experience and engineering background to evaluate patent opportunities, particularly in the high-tech space. Joel’s patent experience includes working with a wide range of technologies, including computer hardware and software, communication systems, consumer electronics, and medical devices. He has significant experience in all phases of patent litigation, including practicing in many of the nation’s most popular patent venues, and arguing and obtaining a complete appellate victory before the Federal Circuit. Joel also represented both patent owners and petitioners in over 75 PTAB proceedings, including arguing over a dozen cases before the PTAB.
Joel holds a J.D. and B.S. in Computer Engineering from the University of Illinois.
Lauren Rabinovic serves as a Principal at GLS and is responsible for due diligence and monitoring of patent investments related to pharmaceutical and medical device products.
Prior to joining GLS, Lauren held leadership positions in the intellectual property groups at Abbott Laboratories and Teva Pharmaceuticals. At Abbott, Lauren developed strategies to protect and defend intellectual property for a variety of medical devices for cardiovascular care, diabetes management, chronic pain and movement disorders. Prior to Abbott, Lauren spent almost ten years at Teva, where she ultimately was responsible for the intellectual property issues for the company’s US and Canadian generic products. Before her corporate career, she was an associate at Foley Hoag and Woodcock Washburn, where she focused on life sciences-related patent litigation.
Lauren is a registered patent attorney and uses her patent litigation experience and scientific background to evaluate pharmaceutical opportunities, particularly related to Hatch-Waxman litigation. Lauren’s experience includes working with all manner of life sciences-related patents, such as small and large molecule compositions, chemical polymorphisms, drug formulations, methods of manufacture and use, and diagnostic assays, as well as advising on product lifecycle management and commercialization. She has significant experience in all phases of patent litigation, including practicing in many of the nation’s most popular patent venues, and guiding complete appellate victories before the Federal Circuit.
Lauren holds a B.S. in Biology from the University of Michigan, a Ph.D. in Neuroscience from the University of Pittsburgh and a J.D. from Boston University.